0001999371-24-005990.txt : 20240513 0001999371-24-005990.hdr.sgml : 20240513 20240513165613 ACCESSION NUMBER: 0001999371-24-005990 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20240513 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20240513 DATE AS OF CHANGE: 20240513 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Tonix Pharmaceuticals Holding Corp. CENTRAL INDEX KEY: 0001430306 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 261434750 STATE OF INCORPORATION: NV FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-36019 FILM NUMBER: 24939971 BUSINESS ADDRESS: STREET 1: 26 MAIN STREET, SUITE 101 CITY: CHATHAM STATE: NJ ZIP: 07928 BUSINESS PHONE: 212-980-9155 MAIL ADDRESS: STREET 1: 26 MAIN STREET, SUITE 101 CITY: CHATHAM STATE: NJ ZIP: 07928 FORMER COMPANY: FORMER CONFORMED NAME: TAMANDARE EXPLORATIONS INC. DATE OF NAME CHANGE: 20080320 8-K 1 tnpx_8k-051324.htm CURRENT REPORT

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of report (date of earliest event reported): May 13, 2024

TONIX PHARMACEUTICALS HOLDING CORP.

(Exact name of registrant as specified in its charter)

Nevada

001-36019

26-1434750

(State or Other Jurisdiction

of Incorporation)

(Commission

File Number)

(IRS Employer

Identification No.)

26 Main Street, Chatham, New Jersey 07928

(Address of principal executive offices) (Zip Code)

Registrant’s telephone number, including area code: (862) 904-8182

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock	TNXP	The NASDAQ Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02

Results of Operations and Financial Condition

On May 13, 2024, Tonix Pharmaceuticals Holding Corp. (the “Company”) announced its operating results for the quarter ended March 31, 2024. A copy of the press release that discusses these matters is filed as Exhibit 99.01 to, and incorporated by reference in, this report.

Item 9.01

Financial Statements and Exhibits.

(d)

Exhibit

No.

Description.

99.01

104

Press Release of the Company, May 13, 2024

Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURE

Pursuant to the requirement of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

	TONIX PHARMACEUTICALS HOLDING CORP.

Date: May 13, 2024	By:	/s/ Bradley Saenger
		Bradley Saenger
		Chief Financial Officer

EX-99.01 2 ex99-01.htm PRESS RELEASE

Tonix Pharmaceuticals Holding Corp. - 8-K

Exhibit 99.01

Tonix Pharmaceuticals Reports First Quarter 2024 Financial Results and Operational Highlights

On track to submit NDA in the second half of 2024 for Tonmya™ for fibromyalgia;

pre-NDA meeting with FDA scheduled for second quarter 2024

Commercial planning continues for U.S. launch of Tonmya, a potential new first-line, centrally-acting, non-opioid analgesic for the management of fibromyalgia

CHATHAM, N.J., May 13, 2024 (GLOBE NEWSWIRE) – Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a fully-integrated biopharmaceutical company with marketed products and a pipeline of development candidates, today announced financial results for the first quarter ended March 31, 2024, and provided an overview of recent operational highlights.

“Our near-term priority continues to be the submission of our New Drug Application (NDA) for Tonmya™ (cyclobenzaprine HCl sublingual tablets) for the management of fibromyalgia, while continuing to build out our commercial strategy for the anticipated product launch in the event of FDA approval, which we currently estimate to occur in the second half of 2025,” said Seth Lederman, M.D., Chief Executive Officer of Tonix.

Dr. Lederman added, “The well-known treatment-limiting side effects of the three currently approved drugs have led to widespread patient dissatisfaction, creating what we believe is a significant opportunity for a new therapeutic. Tonmya has a differentiated mechanism of action and is generally free of common side effects associated with the currently approved products, including weight gain, fatigue, insomnia, increased blood pressure, gastrointestinal issues or sexual dysfunction. As such, we believe Tonmya, if approved, could become the treatment of choice for the approximately 10 million people in the U.S. suffering the debilitating effects of fibromyalgia.”

The Company is also advancing other key pipeline programs including those for immunology, obesity, eating disorders, infectious and rare diseases, many through a capital efficient strategy involving partnerships, grants and in-kind contributions.

Recent Highlights – Key Product Candidates*

Central Nervous System (CNS) Pipeline

Tonmya (also known as TNX-102 SL; cyclobenzaprine HCl sublingual tablets): a centrally-acting, non-opioid, small molecule analgesic taken once-daily at bedtime for the management of fibromyalgia (FM).

●	In January 2024, Tonix presented additional safety and tolerability data from the pivotal Phase 3 RESILIENT study that showed Tonmya treatment was not associated with increases in systolic or diastolic blood pressure or body weight, nor were there any reported sexual side effects. The Company had previously announced in December 2023 that the Phase 3 RESILIENT study, a registration-quality, double-blind, placebo-controlled study evaluating Tonyma met its pre-specified primary endpoint in the second of two positive Phase 3 clinical trials, significantly reducing daily pain compared to placebo (p-value=0.00005) in participants with fibromyalgia. Statistically significant and clinically meaningful results were also seen in all pre-specified key secondary endpoints including those related to improving sleep quality, reducing fatigue, and improving patient global ratings and overall fibromyalgia symptoms and function. Tonmya was well tolerated with an adverse event profile comparable to prior studies and no new safety signals observed. In addition, Tonmya therapy showed activity on improving female sexual function relative to placebo with a nominal p-value=0.010 by the Changes in Sexual Functioning Questionnaire short-form, female version.

●	Tonix plans to submit an NDA to the FDA in the second half of 2024 for Tonmya for the management of fibromyalgia. In February 2024, Tonix announced the engagement of Rho, Inc. as our contract research organization (CRO) to support NDA submission.

●	In February 2024, Tonix announced statistically significant results from its clinical pharmacokinetic (PK) bridging study of Tonmya in healthy adult male and female ethnic Japanese and Chinese volunteers. Results indicate that key PK parameters of cyclobenzaprine are comparable in ethnic Japanese and Chinese volunteers to Caucasian volunteers from a prior PK study. Tonmya was generally well tolerated in the ethnic Japanese and Chinese healthy volunteers. The company expects these data to fulfill the requirement for a bridging study, and enables Tonix to rely on Phase 3 studies RESILIENT and RELIEF results to support regulatory filings for clinical studies in Japan and China where cyclobenzaprine is a new chemical entity (NCE). Tonix holds issued patents for market exclusivity rights of Tonmya in Japan, China, Hong Kong and Taiwan.

●	In March 2024, Tonix announced the selection of two contract manufacturing organizations (CMOs), including Almac Pharma Services, as dual supply sources for the potential launch and commercialization of Tonmya in the U.S.

●	In March 2024, Tonix selected EVERSANA, a leading provider of commercialization services to the global life sciences industry, to support the launch strategy and commercial planning of Tonmya in the U.S.

●	Tonix presented additional efficacy data from RESILIENT at the 6^th International Congress on Controversies in Fibromyalgia in Brussels, Belgium, March 7-8, 2024. The data showed that Tonmya treatment resulted in an improvement in cognitive dysfunction, or ‘brain fog’, measured by the change in the Fibromyalgia Impact Questionnaire-Revised (FIQ-R) memory item. The FIQ-R cognitive item showed nominal improvement in Tonmya-treated patients vs placebo-treated patients with a nominal p-value=0.001 and effect size of 0.31.

TNX-102 SL for the treatment of acute stress reaction (ASR) and acute stress disorder (ASD), and prophylaxis against development of posttraumatic stress disorder (PTSD)

●	In February 2024, the Company announced the FDA cleared the Investigational New Drug (IND) application for the Phase 2 investigator-initiated OASIS trial to evaluate TNX-102 SL in reducing the severity of ASR and the frequency of ASD and PTSD. The trial is sponsored by the University of North Carolina Institute for Trauma Recovery and supported by a $3 million grant from the U.S. Department of Defense, which was awarded in September 2023. The proposed Phase 2, Optimizing Acute Stress Reaction Interventions with TNX-102 SL (OASIS) study will examine the safety and efficacy of TNX-102 SL to reduce adverse posttraumatic neuropsychiatric sequelae among patients presenting to the emergency department (ED) after a motor vehicle collision. The study will enroll approximately 180 trauma survivors at ED study sites in the U.S. Participants will be randomized in the ED to receive a two-week course of either TNX-102 SL 5.6 mg or placebo.

●	Tonix anticipates the Phase 2 OASIS trial will initiate in the second quarter of 2024.

TNX-102 SL for the treatment of Fibromyalgia-Type Long COVID, also known as Post-Acute Sequelae of COVID-19 (PASC)

●

In January 2024, the Company announced the online publication of a research paper in the Journal Pain. The article titled, “Chronic Overlapping Pain Conditions Increase the Risk of Long COVID Features, Regardless of Acute COVID Status,” by Bergmans, et al.¹, found that patients with pre-existing chronic overlapping pain conditions (COPCs) had an increased risk of being diagnosed with symptoms of Long COVID¹. Faculty at the University of Michigan directed the research. Commentary on the article titled, “A step towards better understanding chronic overlapping pain conditions” by Fitzcharles, et al,² is in the same issue of the journal. COPCs include fibromyalgia, chronic fatigue syndrome, migraine headache, irritable bowel syndrome, endometriosis and low back pain. These results contribute to a growing body of evidence that common symptoms of Long COVID in many patients are at least partly driven by central nervous system mechanisms.

TNX-1300 (recombinant double mutant cocaine esterase): biologic for life-threatening cocaine intoxication

●	Tonix expects to initiate a Phase 2 clinical study of TNX-1300 for the treatment of cocaine intoxication in emergency rooms in the second quarter of 2024. In 2022, Tonix was awarded a Cooperative Agreement grant from the National Institutes of Health (NIH)’s National Institute of Drug Abuse (NIDA) to support development of TNX-1300.

●	TNX-1300 has been granted Breakthrough Therapy designation by the FDA.

TNX-1900 (intranasal potentiated oxytocin): small peptide in development through investigator-initiated studies for adolescent obesity, binge eating disorder, bone health in autism and social anxiety disorder (SAD).

●

TNX-1900 continues to be studied in four ongoing investigator-initiated Phase 2 studies as follows: Massachusetts General Hospital (MGH): (1) Phase 2 study for binge-eating disorder (BED); (2) Phase 2 study for adolescent obesity; (3) Phase 2 study for improving bone health in children with autism spectrum disorder (BOX); and at University of Washington, (4) Phase 2 study for social anxiety disorder (SAD). The BED study and the adolescent obesity study will investigate whether TNX-1900 has effects on eating behaviors in specialized populations.

Rare Disease Pipeline

TNX-2900 (intranasal potentiated oxytocin): small peptide for the treatment of Prader-Willi syndrome (PWS)

●

In March 2024, Tonix announced that it received Rare Pediatric Disease designation from the FDA for TNX-2900 for the treatment of PWS. Tonix has an IND to support clinical development of TNX-2900 to treat PWS in children and adolescents. The planned Phase 2 study is a dose-finding study involving approximately 36 PWS patients divided into four groups with approximately nine per group. One group will receive placebo and three groups will receive different dosage regimens of TNX-2900. TNX-2900 for the treatment of PWS was granted Orphan Drug designation by the FDA in 2022. PWS is a genetic disorder that affects several body systems, with cognitive and behavioral symptoms including pathological over-eating beginning in childhood and leading to severe metabolic sequelae.

Immunology Pipeline

TNX-1500 (anti-CD40L Fc-modified humanized monoclonal antibody): third generation anti-CD40L monoclonal antibody for prophylaxis of organ transplant rejection and treatment of autoimmune disorders.

●

The first proposed indication for TNX-1500 is prophylaxis of organ rejection in adult patients receiving a kidney transplant; but multiple additional indications are possible, including autoimmune diseases. Two peer reviewed publications described the work with TNX-1500 at the Massachusetts General Hospital (MGH) on allogeneic transplants in animals.^3,4

●

Preclinical studies have shown that TNX-1500 maintains the activity of first-generation monoclonal antibodies (mAbs), yet with reduced risk of thrombotic complications.^3-5 Modeling studies from animal pharmacokinetic data³ predict a half-life of greater than three weeks for TNX-1500 in humans, which supports a monthly i.v. dosing regimen. This analysis together with TNX-1500’s activity and tolerability in animals, suggests that the protein engineering of TNX-1500’s Fc region has achieved its design goals.

●

In February 2024, Tonix announced the completion of the clinical stage of its Phase 1 single ascending dose study of TNX-1500 in healthy volunteers. The primary objectives of the study are to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of intravenous TNX-1500. This first-in-human study is intended to support dosing in a planned Phase 2 trial in kidney transplant recipients.

●

In March of 2024, the MGH announced the first transplant of a genetically modified pig kidney into a living patient in collaboration with eGenesis, which produced the pig donors and used an anti-CD40L mAb from another company.⁵ Some of the pre-clinical work that supported the living human transplant was performed in collaboration with Tonix and used TNX-1500.⁶The patient was able to return home after the transplant, but died after approximately two months.⁷

Marketed Products – Recent Highlights

●

As of April 1, 2024, Tonix completed the transition to becoming a fully integrated pharmaceutical company. Tonix Pharmaceuticals has implemented personnel, systems and contracts required to support a commercial organization and has assumed responsibility for distribution, selling and marketing of Zembrace SymTouch and Tosymra, as well as supply chain, regulatory and quality control of the two products.

Facilities – Recent Highlights

●

In the fourth quarter of 2023, Tonix engaged CBRE, an international real estate brokerage firm, to potentially find a strategic partner for, or buyer of, its Advanced Development Center (ADC) to align with the Company’s current business objectives and priorities. At this time, the Company does not have a commitment in place to sell the building. ADC, located in the New Bedford business park in Dartmouth, Massachusetts, isan approximately 45,000 square foot BSL-2 facility intended for clinical scale manufacturing of live-virus vaccines and biologics.

*All of Tonix’s product candidates are investigational new drugs or biologics and none have been approved for any indication.

Tonmya™ is conditionally accepted by the U.S. Food and Drug Administration (FDA) as the tradename for TNX-102 SL for the management of fibromyalgia. Tonmya has not been approved for any indication.

¹Bergmans RS, et al. PAIN. 2023. DOI: 10.1097/j.pain.0000000000003110.

²Fitzcharles M-A, et al. PAIN. 2023. DOI: 10.1097/j.pain.0000000000003129.

³Lassiter G., et al. Am J Transplantation. 2023. https://doi.org/10.1016/j.ajt.2023.03.022

⁴Miura S., et al. Am J Transplantation. 2023. https://doi.org/10.1016/j.ajt.2023.03.025

⁵Massachusetts General Hospital press release. March 21, 2024. “World’s First Genetically Edited Pig Kidney Transplant into Living Recipient Performed at Massachusetts General Hospital.” www.massgeneral.org/news/press-release/worlds-first-genetically-edited-pig-kidney-transplant-into-living-recipient (accessed March 29, 2024)

⁶Anand, R.P., et al Nature. 622, 393–401 (2023). https://doi.org/10.1038/s41586-023-06594-4

⁷Stoico, N. Boston Globe. May 11, 2023. “Mass Man who received first kidney transplant from genetically engineered pig has died, family says”.

Recent Highlights – Financial

As of March 31, 2024, Tonix had $7.0 million of cash and cash equivalents, compared to $24.9 million as of December 31, 2023. Net cash used in operations was approximately $17.6 million for first quarter 2024, compared to net cash used in operations of $32.9 million for the same period in 2023.

On April 1, 2024, the Company closed a financing with existing healthcare-focused institutional investors for upfront gross proceeds of approximately $4.4 million through a registered direct offering.

First Quarter 2024 Financial Results

Net product revenue for the first quarter 2024 was approximately $2.5 million. Net product revenue consisted of combined net sales of Zembrace® SymTouch® and Tosymra®, which were acquired from Upsher-Smith Laboratories, LLC on June 30, 2023. Cost of Sales for the first quarter 2024 was approximately $1.7 million.

Research and development expenses for the first quarter 2024 were $12.9 million, compared to $26.5 million for the same period in 2023. This decrease is predominantly due to decreased clinical, non-clinical and manufacturing expenses.

General and administrative expenses for the first quarter 2024 were $9.3 million, compared to $7.4 million for the same period in 2023. The increase was primarily due to sales and marketing and the transition services expenses associated with the Company’s recently acquired marketed products offset by a decrease in financial reporting expenses.

Net loss was $(14.9) million, or $(0.18) per share, basic and diluted, for the first quarter 2024, compared to net loss of $(33.0) million, or $(3.21) per share, basic and diluted, for the same period in 2023. The basic and diluted weighted average common shares outstanding for the first quarter 2024 was 80,879,108 compared to 10,268,500 shares for the same period in 2023.

Tonix Pharmaceuticals Holding Corp.^*

Tonix is a fully-integrated biopharmaceutical company focused on developing, licensing and commercializing therapeutics to treat and prevent human disease and alleviate suffering. Tonix’s development portfolio is focused on central nervous system (CNS) disorders. Tonix’s priority is to submit a New Drug Application (NDA) to the FDA in the second half of 2024 for Tonmya¹, a product candidate for which two statistically significant Phase 3 studies have been completed for the management of fibromyalgia. TNX-102 SL is also being developed to treat acute stress reaction as well as fibromyalgia-type Long COVID. Tonix’s CNS portfolio includes TNX-1300 (cocaine esterase), a biologic designed to treat cocaine intoxication that has Breakthrough Therapy designation. Tonix’s immunology development portfolio consists of biologics to address organ transplant rejection, autoimmunity and cancer, including TNX-1500, which is a humanized monoclonal antibody targeting CD40-ligand (CD40L or CD154) being developed for the prevention of allograft rejection and for the treatment of autoimmune diseases. Tonix also has product candidates in development in the areas of rare disease and infectious disease. Tonix Medicines, our commercial subsidiary, markets Zembrace® SymTouch® (sumatriptan injection) 3 mg and Tosymra® (sumatriptan nasal spray) 10 mg for the treatment of acute migraine with or without aura in adults.

*Tonix’s product development candidates are investigational new drugs or biologics and have not been approved for any indication.

¹Tonmya™ is conditionally accepted by the U.S. Food and Drug Administration (FDA) as the tradename for TNX-102 SL for the management of fibromyalgia. Tonmya has not been approved for any indication.

Zembrace SymTouch and Tosymra are registered trademarks of Tonix Medicines. All other marks are property of their respective owners.

This press release and further information about Tonix can be found at www.tonixpharma.com.

Forward Looking Statements

Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of forward-looking words such as “anticipate,” “believe,” “forecast,” “estimate,” “expect,” and “intend,” among others. These forward-looking statements are based on Tonix's current expectations and actual results could differ materially. There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements. These factors include, but are not limited to, risks related to the failure to obtain FDA clearances or approvals and noncompliance with FDA regulations; risks related to the failure to successfully market any of our products; risks related to the timing and progress of clinical development of our product candidates; our need for additional financing; uncertainties of patent protection and litigation; uncertainties of government or third party payor reimbursement; limited research and development efforts and dependence upon third parties; and substantial competition. As with any pharmaceutical under development, there are significant risks in the development, regulatory approval and commercialization of new products. Tonix does not undertake an obligation to update or revise any forward-looking statement. Investors should read the risk factors set forth in the Annual Report on Form 10-K for the year ended December 31, 2023, as filed with the Securities and Exchange Commission (the “SEC”) on April 1, 2024, and periodic reports filed with the SEC on or after the date thereof. All of Tonix's forward-looking statements are expressly qualified by all such risk factors and other cautionary statements. The information set forth herein speaks only as of the date thereof.

TONIX PHARMACEUTICALS HOLDING CORP.
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(In Thousands, Except Share and Per Share Amounts)
(unaudited)

	Three months ended March 31,
	2024			2023
REVENUES:
Product revenue, net	$	2,482		$	—

COSTS AND EXPENSES:
Cost of sales		1,660			—
Research and development		12,863			26,511
General and administrative		9,310			7,391
Total Operating Expenses		23,833			33,902

Operating loss		(21,351	)		(33,902	)

Gain on change in fair value of warrant liabilities		7,005			—
Other (expense) income, net		(593	)		897

Net loss available to common stockholders	$	(14,939	)	$	(33,005	)

Net loss to common stockholders per common share, basic and diluted	$	(0.18	)	$	(3.21	)

Weighted average common shares outstanding, basic and diluted		80,879,108			10,268,500

See the accompanying notes to the condensed consolidated financial statements

TONIX PHARMACEUTICALS HOLDING CORP.

CONDENSED CONSOLIDATED BALANCE SHEETS

(In Thousands)

(Unaudited)

	March 31, 2024		December 31, 2023¹
Assets
Cash and cash equivalents	$	7,049	$	24,948
Inventory		12,351		13,639
Prepaid expenses and other		10,698		9,181
Total current assets		30,098		47,768
Other non-current assets		105,245		106,689
Total assets	$	135,343	$	154,457

Liabilities and stockholders' equity
Total liabilities	$	27,200	$	48,932
Stockholders' equity		108,143		105,525
Total liabilities and stockholders' equity	$	135,343	$	154,457

¹

The condensed consolidated balance sheet for the year ended December 31, 2023 has been derived from the audited financial statements but do not include all of the information and footnotes required by accounting principles generally accepted in the United States for complete financial statements.

Investor Contact

Jessica Morris

Tonix Pharmaceuticals

investor.relations@tonixpharma.com

(862) 904-8182

Peter Vozzo

ICR Westwicke

peter.vozzo@westwicke.com

(443) 213-0505

Media Contact

Katie Dodge

LaVoieHealthScience

kdodge@lavoiehealthscience.com

(978) 360-3151

EX-101.SCH 3 tnxp-20240513.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 4 tnxp-20240513_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 5 tnxp-20240513_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT XML 7 R1.htm IDEA: XBRL DOCUMENT

Cover	May 13, 2024
Cover [Abstract]
Document Type	8-K
Amendment Flag	false
Document Period End Date	May 13, 2024
Entity File Number	001-36019
Entity Registrant Name	TONIX PHARMACEUTICALS HOLDING CORP.
Entity Central Index Key	0001430306
Entity Tax Identification Number	26-1434750
Entity Incorporation, State or Country Code	NV
Entity Address, Address Line One	26 Main Street
Entity Address, City or Town	Chatham
Entity Address, State or Province	NJ
Entity Address, Postal Zip Code	07928
City Area Code	(862)
Local Phone Number	904-8182
Written Communications	false
Soliciting Material	false
Pre-commencement Tender Offer	false
Pre-commencement Issuer Tender Offer	false
Title of 12(b) Security	Common Stock
Trading Symbol	TNXP
Security Exchange Name	NASDAQ
Entity Emerging Growth Company	false

EXCEL 8 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 9 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 10 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 12 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.1.1.u2 html 1 22 1 false 0 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://TNXP/role/Cover Cover Cover 1 false false All Reports Book All Reports tnpx_8k-051324.htm tnxp-20240513.xsd tnxp-20240513_lab.xml tnxp-20240513_pre.xml http://xbrl.sec.gov/dei/2024 true false JSON 14 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "tnpx_8k-051324.htm": { "nsprefix": "TNXP", "nsuri": "http://TNXP/20240513", "dts": { "inline": { "local": [ "tnpx_8k-051324.htm" ] }, "schema": { "local": [ "tnxp-20240513.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd", "https://xbrl.sec.gov/country/2024/country-2024.xsd", "https://xbrl.sec.gov/dei/2024/dei-2024.xsd", "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd" ] }, "labelLink": { "local": [ "tnxp-20240513_lab.xml" ] }, "presentationLink": { "local": [ "tnxp-20240513_pre.xml" ] } }, "keyStandard": 22, "keyCustom": 0, "axisStandard": 0, "axisCustom": 0, "memberStandard": 0, "memberCustom": 0, "hidden": { "total": 2, "http://xbrl.sec.gov/dei/2024": 2 }, "contextCount": 1, "entityCount": 1, "segmentCount": 0, "elementCount": 59, "unitCount": 3, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2024": 22 }, "report": { "R1": { "role": "http://TNXP/role/Cover", "longName": "00000001 - Document - Cover", "shortName": "Cover", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "AsOf2024-05-13", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "p", "body", "html" ], "reportCount": 1, "baseRef": "tnpx_8k-051324.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2024-05-13", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "p", "body", "html" ], "reportCount": 1, "baseRef": "tnpx_8k-051324.htm", "first": true, "unique": true } } }, "tag": { "dei_AmendmentDescription": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AmendmentDescription", "presentation": [ "http://TNXP/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Description", "documentation": "Description of changes contained within amended document." } } }, "auth_ref": [] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AmendmentFlag", "presentation": [ "http://TNXP/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_AnnualInformationForm": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AnnualInformationForm", "presentation": [ "http://TNXP/role/Cover" ], "lang": { "en-us": { "role": { "label": "Annual Information Form", "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form." } } }, "auth_ref": [ "r14" ] }, "dei_AuditedAnnualFinancialStatements": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AuditedAnnualFinancialStatements", "presentation": [ "http://TNXP/role/Cover" ], "lang": { "en-us": { "role": { "label": "Audited Annual Financial Statements", "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements." } } }, "auth_ref": [ "r14" ] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CityAreaCode", "presentation": [ "http://TNXP/role/Cover" ], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_CountryRegion": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CountryRegion", "presentation": [ "http://TNXP/role/Cover" ], "lang": { "en-us": { "role": { "label": "Country Region", "documentation": "Region code of country" } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://TNXP/role/Cover" ], "lang": { "en-us": { "role": { "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "dei_DocumentAccountingStandard": { "xbrltype": "accountingStandardItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentAccountingStandard", "presentation": [ "http://TNXP/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Accounting Standard", "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentAnnualReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentAnnualReport", "presentation": [ "http://TNXP/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Annual Report", "documentation": "Boolean flag that is true only for a form used as an annual report." } } }, "auth_ref": [ "r11", "r13", "r14" ] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://TNXP/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://TNXP/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentPeriodEndDate", "presentation": [ "http://TNXP/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentPeriodStartDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentPeriodStartDate", "presentation": [ "http://TNXP/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period Start Date", "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format." } } }, "auth_ref": [] }, "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentQuarterlyReport", "presentation": [ "http://TNXP/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": [ "r12" ] }, "dei_DocumentRegistrationStatement": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentRegistrationStatement", "presentation": [ "http://TNXP/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Registration Statement", "documentation": "Boolean flag that is true only for a form used as a registration statement." } } }, "auth_ref": [ "r0" ] }, "dei_DocumentShellCompanyEventDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentShellCompanyEventDate", "presentation": [ "http://TNXP/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Event Date", "documentation": "Date of event requiring a shell company report." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentShellCompanyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentShellCompanyReport", "presentation": [ "http://TNXP/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Report", "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentTransitionReport", "presentation": [ "http://TNXP/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": [ "r15" ] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentType", "presentation": [ "http://TNXP/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentsIncorporatedByReferenceTextBlock", "presentation": [ "http://TNXP/role/Cover" ], "lang": { "en-us": { "role": { "label": "Documents Incorporated by Reference [Text Block]", "documentation": "Documents incorporated by reference." } } }, "auth_ref": [ "r3" ] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressAddressLine1", "presentation": [ "http://TNXP/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressAddressLine2", "presentation": [ "http://TNXP/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine3": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressAddressLine3", "presentation": [ "http://TNXP/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Three", "documentation": "Address Line 3 such as an Office Park" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressCityOrTown", "presentation": [ "http://TNXP/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressCountry": { "xbrltype": "countryCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressCountry", "presentation": [ "http://TNXP/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Country", "documentation": "ISO 3166-1 alpha-2 country code." } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://TNXP/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://TNXP/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityBankruptcyProceedingsReportingCurrent", "presentation": [ "http://TNXP/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Bankruptcy Proceedings, Reporting Current", "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element." } } }, "auth_ref": [ "r6" ] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCentralIndexKey", "presentation": [ "http://TNXP/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r2" ] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCommonStockSharesOutstanding", "presentation": [ "http://TNXP/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCurrentReportingStatus", "presentation": [ "http://TNXP/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://TNXP/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r2" ] }, "dei_EntityExTransitionPeriod": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityExTransitionPeriod", "presentation": [ "http://TNXP/role/Cover" ], "lang": { "en-us": { "role": { "label": "Elected Not To Use the Extended Transition Period", "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards." } } }, "auth_ref": [ "r19" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityFileNumber", "presentation": [ "http://TNXP/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityFilerCategory", "presentation": [ "http://TNXP/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [ "r2" ] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://TNXP/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityInteractiveDataCurrent", "presentation": [ "http://TNXP/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": [ "r16" ] }, "dei_EntityPrimarySicNumber": { "xbrltype": "sicNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityPrimarySicNumber", "presentation": [ "http://TNXP/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Primary SIC Number", "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity." } } }, "auth_ref": [ "r14" ] }, "dei_EntityPublicFloat": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityPublicFloat", "crdr": "credit", "presentation": [ "http://TNXP/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Public Float", "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityRegistrantName", "presentation": [ "http://TNXP/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r2" ] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityShellCompany", "presentation": [ "http://TNXP/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": [ "r2" ] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntitySmallBusiness", "presentation": [ "http://TNXP/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": [ "r2" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://TNXP/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r2" ] }, "dei_EntityVoluntaryFilers": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityVoluntaryFilers", "presentation": [ "http://TNXP/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Voluntary Filers", "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act." } } }, "auth_ref": [] }, "dei_EntityWellKnownSeasonedIssuer": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityWellKnownSeasonedIssuer", "presentation": [ "http://TNXP/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Well-known Seasoned Issuer", "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A." } } }, "auth_ref": [ "r17" ] }, "dei_Extension": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "Extension", "presentation": [ "http://TNXP/role/Cover" ], "lang": { "en-us": { "role": { "label": "Extension", "documentation": "Extension number for local phone number." } } }, "auth_ref": [] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "LocalPhoneNumber", "presentation": [ "http://TNXP/role/Cover" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_NoTradingSymbolFlag": { "xbrltype": "trueItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "NoTradingSymbolFlag", "presentation": [ "http://TNXP/role/Cover" ], "lang": { "en-us": { "role": { "label": "No Trading Symbol Flag", "documentation": "Boolean flag that is true only for a security having no trading symbol." } } }, "auth_ref": [] }, "dei_OtherReportingStandardItemNumber": { "xbrltype": "otherReportingStandardItemNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "OtherReportingStandardItemNumber", "presentation": [ "http://TNXP/role/Cover" ], "lang": { "en-us": { "role": { "label": "Other Reporting Standard Item Number", "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS." } } }, "auth_ref": [ "r13" ] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://TNXP/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r7" ] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "PreCommencementTenderOffer", "presentation": [ "http://TNXP/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r9" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "Security12bTitle", "presentation": [ "http://TNXP/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r1" ] }, "dei_Security12gTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "Security12gTitle", "presentation": [ "http://TNXP/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(g) Security", "documentation": "Title of a 12(g) registered security." } } }, "auth_ref": [ "r5" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "SecurityExchangeName", "presentation": [ "http://TNXP/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r4" ] }, "dei_SecurityReportingObligation": { "xbrltype": "securityReportingObligationItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "SecurityReportingObligation", "presentation": [ "http://TNXP/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Reporting Obligation", "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act." } } }, "auth_ref": [ "r10" ] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "SolicitingMaterial", "presentation": [ "http://TNXP/role/Cover" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r8" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "TradingSymbol", "presentation": [ "http://TNXP/role/Cover" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "WrittenCommunications", "presentation": [ "http://TNXP/role/Cover" ], "lang": { "en-us": { "role": { "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r18" ] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-23" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "g" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12, 13, 15d" }, "r7": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r8": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14a", "Subsection": "12" }, "r9": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r10": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "15", "Subsection": "d" }, "r11": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-K", "Number": "249", "Section": "310" }, "r12": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "240", "Section": "308", "Subsection": "a" }, "r13": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Number": "249", "Section": "220", "Subsection": "f" }, "r14": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Number": "249", "Section": "240", "Subsection": "f" }, "r15": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r16": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r17": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "405" }, "r18": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" }, "r19": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "7A", "Section": "B", "Subsection": "2" } } } ZIP 15 0001999371-24-005990-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001999371-24-005990-xbrl.zip M4$L#!!0 ( :'K5@C[O<2A3$ !O* 0 + 97@Y.2TP,2YH=&WM?6U7 MVTB6\.?'Y_@_U.;ISL(-@TJ&; (/I[IG]LJWJR));)4'< MOW[OO54ER<80E-A@$]&[$Y MZ5;5?7]]\^'RX\G;:N7-AZ-.%_^]/+X\.7K[ MYH7^%RZ\L)^\.^O^!_ZU_[WYKUJ-O9?"]UZQB\07M7,^%*Q6>_NF>_P[ZUW^ MY^3HIV=C'@UE4(O#R2O6FL2OF;G0#^,X'+]B;;QV+;UX](HU&XT?G\W M_];\;VX%+V:60.L[SX.!X,&S+N58*'8JKME%..:!HR\XK"[+8?"*^6(0PYH[[,/%T?N?GL7!Y//_[G^J-7:;[=9.?12/G[V]# /Y MF9V/>#3FKDABZ7)?L0^A[\E@R [#:%)G-;9?^_7-BPXL[%P#/V$JGOIBIFK+[TP?[P 'SRI__;H\TCV95RM'!S4&\TW+_JP)/S> M$E8&WT5T:=Q2$F810KP,5(Q>Q? M"8\ '-9JM';@4L #5W(?OJ02'[[$ X^=343$8QD&$+;ZF;(U,"E2M?Q)(!/PNJE3A"=A.'3"7]L8S9:;?#9,#BD6!*N"&< MV8C[ Q8.]+$.PH@!,HRG_#G,1>P][H=R1$#%>K10LR5_Y3#](59;(N]-P _#\5A$R&&JE8G/@P"/ M#4X'CB^!9^%I_5;OU9G/D\ =(0)KO'489Y,P!I"0.07PR@%RKYHO ^$0J!'W M_6F-NX@(#@O"H!9.9"@]X&" X4))EYZ.) *P@N0=PTWP@FHE3P>KW=(_$Q7+ MP715B&&Q8L7@+Q/DPP^=RP^=CTZUZPCWS*FFU'LZVMGT_.WAVQTZ,_ M>G\<7QQML^>!Q]7H-;N/DK)URI7'_P*03O]]OLVV]#T& P -)SR8;B-:#1)$ M' G(/@0I)[QJI2_#R/!KV(0X]6"'@?0CXC>PI%;B1$;@&21$M43Q;IB5 3_!@>R*@ MBG93;Y!#+P8HKB1^R ,67HGH2L+N PB1< G#<$[E KO>HGD#X?DSWWOKR1\ M?99$U4H@.)@4(AK#N%EN(HUY6"8\.C#).(7M>-DB'K3"8^ M("4>*2!YM[.]0+QON5/7#_LB^)O#:P E/QSZ^$Q SV&"O#?F?5_$:GLQ3YQ1 M#1QV/9*^L& BA2&(@ M!GH"2/=$@-%&1_:QW@5V D3G,$,PEG.NU\/W:IR"\AF..!(\10T'J@]*+B*B \3$Q& CD MPG!FB GQ*!)YE-'X!,CG ?4HP! X9M0, 8.NX78%6B0'S 2"@N]7*QZ0'?RN M!JA*A+ %U]+VN6(QXB-?>#R@+%, N,'"(:!!)SAQ&K1L$H")&K$?DZ*"L 4 M\0E)DKHA4P "[_4D0!Z13H/$,1;NB =2C4DKT:\G#@\O&HI D(;#!K@Z6"J2 M''P^LP-%P_(:%Y+5 NL"&7L.0!+'B8" <)5(7C M )D ?!4V0L'M?3\,\2%"J20"[6O(@>9#%*" '2AF8 >1FY'F_1G8#?.F:@ $ MCPNJLXX"3N2.G/Q66B5/#E(H8>/#!%A,'PA[#.*0CM9B &W * 12S=@,WO>9 MF .LM=E@@(\^[N!$A!-@7X9/D':I$MQXXF1PR1-]ZA4HCAAR/ MDP#4D.'482 .%5"FPPPY Z&3#X_( ]=AHE6Y2(>"6($B._P\1B! ;82)L,1 MD*W+)X M/J(*"#9!*SR&UVSUQFC_[05IR-5*YM-*+8Q? <7.C;)RF.KO_UB-AW#U9 66 M]YOD[:$VD\'6 BL!D;TW5;$8LZW#T]XV.S<4]>9%\G;)9O!#KE.+DFIEBUB' MUAQ VH(56&LV6JQW I1PIW+,K&[\"FG]#L^"P]08/F+CT ?UT1!YG]J=87L&H <4(@WP.B MHF_,!U?R<16S:W2F<)J^/P$=$P[RIV>-9_2WFG#7_FU0,!38V_13N14/5%>>2AO2*-;T7Q@8BG).)C8 @1)Z5R MRD!P<%#:PS'1_$1>A:@[G(,%((I!TF871[WCD^.CTTO8B<1#E02XBAJ%UP") M,2PR#?D:F%X0QC=L JO'H\+$% @ H&^W&"3 OSS)]9USU@!^U@\!-FU/(+N, MX/>(O!H1LL@I:"!H)@$\QCK(FS#U8I!<9KX\L*D(C"M4X_R\CPW6V05)/^YK MWW];[QN>!IW"S8UU&"\&1B2&DG1 0(7:7[ FTC.]$&2*J*%< 5DQ 8XJ^F&- M]+[01PM4GZ*XXGZB55(XQ.F8@R$8,PG*",8WU$2X8%^B6[((1"#8QHBV(O F M:)K-N4G05+X.V20$C1C='G8C7("5')Z@FH+\=/+FK8\G!PH1 %H,%I* P/D! M!/*C1MKX-AO"MB8UW 'Q4Z/>@)_=;805U6?R&J':3'@[8XVQ'IIKBK@B2M:.)=PE54()$.D &HK\F9,A>T1O+&QY,6#L^=PT M7R+A$]'"3LDQ^7C1W^$+,6$IAMGS2 UV;6'8KQ=$&>T!84/0C= ?32BI;19T M*^.R9W04-1U/0*SI;V3FO6%$R'[0=V.885P4@>G,R2,$[U;610@+&VA?).(1 MR73$)/2D$C5)H<$)0G*]&)Z,)XX!@K"O0/$57D$F(7P"+'Y&[)T4^SP?I3'>$8\6"H MF7Q/O_^]>3]"]J\$?35A$' 9%80#5AR!^ VCL6,7B">$9S\C^U]<7FB[X7$U MGA7:NK&WEAK. BA?Q-';>Y[RHQ]8J:*:M)TB1(FA=)7+!P'&B2DA< %YP?O[ M9H]%/[JA0F?:&<5_@F'.$KX8A0[D/2[LD>3'.> MD&>/!/?C$5BS'KR>D;9%ZK96O$0\ B#8+QSL).!V]-'A2.+OQ>"X"OTDB 7H MTRSB8I_!%"L'-.5+!M,NKYK+@Z=RQG!R$R+P/ M>>)R)4',Y:[3V7!C#0"LM)W6("EH??!\R'76CK&B]"YH[;'E]Q5]%2:/J."V M?)Y02!)>"H\F?Q)L 1BI8 KY!$HD_DI D26%>!-;P.!MO6Z>'1=MWLR2CT/54,$HIU4_J M"$SVELX/@V,#@UYILS#2T:49TB; '0VUPSZ$<%B_XO_@4BZYO.8+E9'_AS_X MXMROI8*R^0I*J4P\^JD6529T,N;M5HT2OM >'^-NM78,FE<)YA21?7#/+,(U\[<&-4;<"L MY[2#B?:^X,2B3,)Z9+,89W@,4X9G%590D<68V(4O!\!^,3?+)271@SV*IDY> M'<5O&UZ79F_-,CUFZU-*ME>RO17\E(SNT3'A:SSMBW(_*!.4N_EDCYQ9K)G- MWAM@/6_CT9L7^"\[QGS&@)L''(+AAQD4!5E-@#?&F"X=*6,.O\^':.'O=U&B M@!O#)KP3<"T9.X9=OZSMZRHB[9D@R$TT$QT^!?,PYK-/M - .TNXC8EJ!P6E M 0P#G7B0RPQW,'?DN:\PS;H?8;; (!P^C^CO@NKP6'!,1O%L,-2E8*AER#-; M=#R>H$8^$Q"M78@KB9GN6^^/_U6[V(;GC=%O(6,Q_HH$%7I(;LWX&+O5-H8[ MMT%Z/VNTGR(M3E#L2J5Y).:SKXKQJSM"R(VF=A91/@Y#:D&1UJBWFS>E&/Q/ MYQWU;5A-I?R*,D1U*FBUTCM)#:"9R@+N)K% M0 H$C#95&)L=7J "E3JE__< MII'CY]WMM"1O,IKZ_#.ZG;"D0L4S%8'PCDFH8M [DC$GI_&-AYU?PM,*9X"V MR@S0,@.T%/JKC!GERH?G_#T89G?!R(G,W\?!%0J5H17R:07GUO%I=QL+EFP= M9S& +,_2GO@6%IV8]X113:*0(:%QUND=]W0B'QH^)LU0Y#+A4=*D*614I7@9L!:]29KP#6(-+LR'S0I0^0G6E%0P,$C%%-P@"X72:E?PLD*3)Q MP?@(O.843+H1.^01L*H A#HP7!DCDZ;!GA)""C2/+\9N<@"D5#)3+ ]L_B'AK)>=WM814ND J^\Y&X= 7<"'X10I_Q"0 MA?)%BJN#^9T-,!-XOG1QO\'T#@"61E?R*HP4&A%'77,K4(C6]5.4.\]ERQ9- MLX3W]P4#I/= %_P["V_"Z^AT7($Z*T<'=NU:B$]8EHD'!0]Z*AZ3TK?QZ&?V%;Z-K%.#FE$P\IH$,0RK9,QE%=I>)2:Q M\+NQ%_,.A=KE="+8"H,\,8']0A5-;P1_9W:ZZHP0Y@*V8I; M+A=2?<*E950*1AZ/DPAW_4(,03WW465&^X4H57\':XX2E7:5 '+MNTWT=DMJLO=-L$/@S(/B&8TBJ@F?VD99D%%521WW,W M\=%JB.>,0GS#1["AP- - (I(!QAU^IM&T#JC]G)!C-@>:C2=0[!BL!AL[ #9 MB@GP+#3<%.Q#C%(.#@D B[$YP/V.(T.<@CLBX[_=$8\ )U-$ ]QQ:)-;>I/U M=9F:!8J/A K2+4,F"*(N6I1]>LSZZ*B?$6"XI2=+F M'Z9--JA.C(-Q'U[CR5")*EHP&(@&!JBIS;;4,2A=V N1XR=P#-0U)"5@3(V% M5_A 4C%5-X*EYT6 VP$R$M-F .Q=W9A!Z<8,:4<@M7)=ZF%Z,Z FU6XTJI6M M"-OZ]+'[76P*9=DXB?$O-W0)=P1L000,:/L5ZTOLX6(Z.&)POX9-GC#E4K>/ MU#?(( 8K6DNN4H$J%:AEFD9I#G:8&3\\-9#28H L@]]@^F*#81'&%DWXR_FL MHC [-DLX*FE8VG- M'4LK^2F]58^.")EF4.3@L(UB']LR$/,!3O8.0\VV4]NEJ='W!#4 ((/6A)K> M=SM/2*,Z((U*H@H9<(7I'":=&[V3?5 E1N"[)CKK0?7P\"60U$N4!)C@TL*P8649E)D[ND0G7+C/A;LN$VQ#5YDWR]H(:\79U M(]XGTZ 4B+GU=2K;0F?".;;\CVI_8/Y2ZE9E6^=_],HP8JE$/52Y*\>6A39= MR&-(N>Q<>"9MRY)PWA2SKJ*"P9!N1R?U&2JZA2;^Z*4U_>CH"MCQ:3?O$DH] M=CD3J'B=EX4!L\CP]?A>JF^P6@TI+*EN8)I 4%W9G$*IFYTS+U2B-I 44BK> M$2'??WPVIZR]1Z"ET0A/ZI$QZ(#4RN\0K+^)K0O(WUL,C( BR,(\K\[.X$_Z M52LW-IW,=K+3^A-.-$C?G_M6.A\!]X4/"V(*-N6$8U7YDZI_&6]T[P_C3SB+ M)B- 'O(NYG"W&""9SP%Q YVP=8TH>.+8900S'5,]DTB)&QV/I8-" M0-%T2&D]2?&0F=47T6%MP[=9!3D@R4B'6^!S#&?64C436'B@+22-XB-L_4I! M.%W:6;BC(:U/8,-3WJ=NLC:_\VEX9T"%.4XG$%0K3TB!:>Z2 H,98[7#[D[C MA+UW:^/0TPU11\D8.QK@3),P"%V?G/OX7<1CT&KBD8P\TV#'3#E)G[/@#J+5 M?$T-CD3"I@F8)QLHY*? O"/QI\AFILP6]"1Q2*,@1#;UH?0PE?Y"1,Z0%YVDU.S+"NNB4@]E)VD [)/T C'-$0F8 MMDG,QO!TB2-QM7017R ME<[5:CL[.N/F;@%5,I*2D1"8YT"0W]3BC.:58;5PH%7#E!C&'+1WK"W5'LBT M _7 C$;-B=>;,A6>7-!=/.[TU;;#IB+61*GK=K+L0(P?C0'S@'ZPRUU*U89L M:KNF\/UCZ*$2-+0++,AFJ<1\YT4J8=9>N\C)VIJ'(HB$=@@X'F).M7I':@/8-;8$P4 M- O1&(#SF1;.@8N!:Y&3>(95IKD5*5[<&$R1<38'P!T.A:(>@R;O$J14+ HW M< R _0!_IZY6@YO O'=IR8"19)6##2'068#]-+5UQ88A<=J2MY:\=>65O(MZ MMA'K$FG3-KR2Y7:A*QVN(KIJWTV3(1G[14UP= :1J8WNGKF<,56PZ,XS"F6>T>L2"O>A- S@^E^ @?_:5 M@ TMR,3LT@TGU (,J(V8:N8@PQF3- -2I9*IQ8=T-M1J5: M3D@9+UE3R9I6YUPWR9JZ2 <,DSGFI&W,'%Y2>8[Q(%*GXM0#,Y%#@\=%T9_R MY'UIAECJD3!4QN#[O!\:A9)T#8'&%.@K5N?18V4-K B !VIGI+D%F%\%6]7P M6:]0IV]U/ST#U'12UMJEU2U[&/DR_!"+95+>3;:D'I=E"_^+E[.;3=$\*7<* MZ#">B A'HNALD@5[966-WHF,WQ'X>P6+J&BQ) W,^5 RKQF&$XDXB4" X%;H MXG7MY;;@.N0#H,074]O^]=Y^;&I*ZJW1\E_>QS1^*7-=8!G=YG36?&*C%V MB!&FQ+W)5:M3%UULVX8>WD&"4A_5XJ&>36"TU"=:;CB_#Q/3)O@S5 M=!QQ:K)-HR*XLGVVW1&7@9.??GR,7M<3(T H3["[F"XN5C\2HF\/:C\).(4"\"VVUAT2G!3W_G>XAE=/1&6ES)M=$(G7N MNDE$N3K]1.$0')7W4>FFF#*,B)SKK(-.YL*>;HGEXOG^%5XH])!C"I)H<2%C MVT25DHQTEHFOY^3T$^DC+P NH<.\T.W> M54V:)"/A.>+#W7K9B.)%/-&X8 M6XB%23QR9L./<#(*[=J9W*R=7:?1:#"%V%8TZ!S"VM_U3FHM-M#,';NQ !-6E&[DE&BV!5W75P%GE7!_"93G?T4BM3_T?%!:](]W.7G M%+>-I&4N=GOPJ$$2.D_E7(?' -[C1F.SQ:S;)#;.>V\3V'3] ML =J=3K(FVV]QSIBKJP*[HD NVJD@3_=\N[FR,P;4S"K%=,?>V1FLC\D"CQ< M9ACU? %@R0=D6^.PBY[#J%])G;K_=(Y/,0):-PTONV?'>'^]V3AX^>+/.O7P M:.1^VLUF8W-WHV5W(]?"A7VL=;YM1UH'F[LC;;LC)R 7)2I7/]?SN]$9LU^P M8:MQ5G+;R\/NSBB.)^K5BQ=>*.M@$;Z@C6KNP4;Q/^,Z?:P.[=@= M^BB3B+->H>V9@<4%^1.A3S$1SS 5];Y[MZOS4\W^;>@V[J;;>'?^U\0T>7N8R4RFH':EE@H(9@UG20HY9&/#')%R2GPJB%V9P#O3G;B\SNC<&/ M/8L?G0#DO\,NZN>6TI#03JD=G":M/>R:TCYH&Q_$3J/)MI!:MF]A1^W]%VJG MN;N_5X,OU1I[NP<[M9V-WJR7=K-Z<2C=T&&GQ(W>A2H&/>EGG+2IM^HCG[*F M)IYV2CR(V_ )F(ZC,*L0TL',F[%VBO+E8YHVJ0@--8PJHA*%X2N'Z34QQ:>V MM]I&"L:%>O7=(:?=,N2TPI"3<98]@(M3NS.KEWF-O-/1\+XHX?<4B M%R#Q_,KU_R\['()M&TEPM.=B'-AH\H>7]4;:>A\[8\':=1@!?\$ PA7W,?'& M,8.E=?+/#R";#]+[N-*=]EW=2K^=,J!3$>L'Z?0#":^8F)Q8I8/F,YZ8'YHO ML7^Y>2J:99I)63^@!CX/1Y!_ 9M]/H#T0[N5 ]-8BM4*-6>$+\K0,Q5A[64P MKD(SJ !Z=P1V\94)[JYL*&U0>B:;=1=P&QE M OI8,(\$]R^9@'R@;F.A(K>,*X2GJ%W8W%GNU'?2G;>];3BEGV)?07B-;B$* MMPXH8;6^=/=&?LM7+Z>3MZ265BO_RF%KQD7L6/<9W7[#UGB*#7:M*RX25R)( MLIKXFZ2ZB,);]5V+%9H]S#_.Q3"BHBI\FD[9EYA0B'2NN*^S+6T4\#D@T^MJ MQ<8"Z<]\0) NI(,_L,Z1NSHBJI66DZPIQWRMN%;.P9&=M5'Q'/>52O1(%3.JBW;SFDESF^_H4S$FD3 MZVJ%DO0H>5IFYZ-)>C;,;UOZY'(NE!U)F\(/%@VV"8IM%^Q%\;"(=#OR/!NJ M'Z=Y1C9RC]('3'X]A,AB"S6D2OEV)# 7XDF@!O%O'P4WGL8/6TU0XK:S8X;# M_&$+#.C];>H@H$9PY@[K9]7WVEL:7 #Q);!N'5RM?$&#[#6?_Y8'3 M;.S/K*W9<%I[^PZ6"YB'W@7F2KP/#Z79]&W#WOF,I \A17.!\J*)3D#]ATU M78K)]"C+-6NEYA"4WE7+I7?U93B;X663MIA5GL.TJR/LC,-\X%N!LGPM/VW; MS'R+^(0>I;(F)CI8C_H0D*O.=C8EO+J?B>^+*VJ K!*K.\^%2_.2&;G7( 2: MPP*.')2WM#S?.CSM;>>J]&>?C)R3L@BH'(12Q?J@/L%6X0;K(%XV5H]MG9I. MP+G^&[D>R5@5:'/N=5B/PG3YX04XM_Q&\%?3K-;K, \+X#[5.@ ^'':;NSO;=N)&>L06 M50QUV@DM6+D>\4$.< +U1H<;\L4L+LS7Y0F(5R.^,-UAKENLM-,UA':^1)@. MD><2,A@0*(FRE^U;/F)1+F::H Q.HGR.)U"SDI[DT=0QRI*:M;;8K+&UI7!. M8"0G,65AF<5O \&-AS @YLEH6N=]5+I,C12H<7UAQN6!^7!G\A-F MSL1XF[:?ZZ!UYD(A2]7;X+^]A_&+V,->JK>C\5"35?MOWX<1CB"J5DY";"XQ MI!&+Q)L7UEENP*(.@9EP;)NCTI5H6TF'"/(8'I&(PO77?+-\-"J,9346/#!) M^C2*-Y)7G&;&NHDNHF GTFI$[ +UX3'K4#B3-0\.=LT@O!DXQGR*]((3[V+= M)<"(V$2/\[X!38C3#A4Q7663>;(9P>D@3/-)7_C8SF?^,FKJ+E>QO5ZMF ]0 MHQLO>(X>M95>14Y@/M&E#=DG--6=.+JR@__FUY!;/FYXGQOO$W&0_P:V8ZM6 M]%M-Z)[<7&Z2)\F9T%""0BXEW [QJS-7$&\ MU^6XS^:Q9+^3%T(_LEK)GFD[(X<4"B!=0Y\5'<7M*TSWP+S;.&MTP3\"B"J- M+\>4JAB'#K7N(H3DL7'08';"@$L_T9UAPCXB,WG.7,#:"'T?I'-KG0A]L*:V M0;?\PL^UA8RWF*I'W-'7"]_%%S\ESP6W#+&O;J"AB4P[5"SGPH&1TQ"5$#GN)Y&B@WUM#PU[G)I1O#?B MGX.!;C=&UR=8 81GD4S(MV8?+W&--'LGZ6, BO+R!,I8JF=:QW; AIG5\YZ MFFG>:?ZE3K42I\B?]WKJ$S*,+'_#3"&L0:$;CFEN_5IHY:4EKD;FIQ5?!$W, M/Z&J4*V$?=_R0D"(9(+'R4+=9Y*TB>GM=(.C\6R*B1H1J4:"F\FRV-S.TA,& MZG"71W9IG2!(*+."JI6Q+?1[9,/-1NW7U-R8PGDQ79!U(T')T)4*VDJ#M$#A8*D:R*)-]]X M1+D&B/!INQ#:/SK<<& 4YX'EF5_BLGQOZN5\P^=BX^=PZ/?+H\/.R<]]N'LI'M\^C,[/+LXK[_I MXU3$P[/3[M%I[Z@+%T][9R?'W]MC9>W9V?G31N3R&+^B; MMHY!W0&^IH#4 !#@* +6WQN1R@+4=PZTI__JC,&4BM6VN2\)>$+U MO+5L8? M8%-O-XT*=0:X_^(,#5'OIXD"4.QO:0D^MA=X1BB[E*8 FEZ>61KXFM)[LP$I MZ357ZIQ>U""@'X*X74M0LVV%@P3,"'YZMI>BQ=T,T_:0N/?B5DL-E]CB5B]' M-^LR^H@F<[RH"\&2ST_T\!40VIJFAQ, MA/_F-FUF!?L_/A21?"V$S15O\0_+VLIFZ\<54W/+V=EO+0W<%>_K4EA/B:>; MB*?/QU3SOL&8^D RZ8^1C,6:*-,;H"I\ Y%N *=;?T5P [:Q1, 2 3=/#BS5 M-EGE%AV>]2Y[&K;.:9<=_?LIHR86-,B:SY%X(WEP!? MTN[3I-UFR]G?NSN3XDEL8XF :XJ K3UGM]G<- 3<$'OBYKZL/-\I;4]HAWADB[ZB4LG3<<..WFMQLV"S!F(]ANB>G?#Z:_=-H'WRX$ MUP'3GX)5]4"T=QG&5E">Z;;VP9 =F2:T)?LHVBVL]_^=BMN'?A'B>HE MJM^UAG;;.6A\>\[E.J#ZAAB1:T?PI2]G37TYFQD;+A&P1,#OP9FX,8&HU!C2 M\.&$B9)@UX(8EDZP6ZVFT]Y=;_?_=HE\3Q3YEF1+/!SRE19#28)/B@0W4V$K M$;!$P-)B6*,M^IE:0E.N<\!,0T\<\L=EQ*ZXGU#[Y6L>1=@]U9>\+WUJ 5I2 M]5I0S K"J8W&[J81=8E_3P;_RHSH)Y;5=H:=CC7 6V9,[#;V?P_'2^K^4H8P MOY\0YM;NP0;&ZK_5#5;B^/>$X_L'+SM4Q%ELGO$K+GT:^A"'-&D(I\C$H?MI%/HX8W[IBL#2U_.U MJB,!PKPP@<6OB_9X6UO"E2U@^?91<\N1,#2@EJ.!;78;L+)HNEU'"#HX'QEZ>K>/-)/ M8N&5^F:I;Q;2-QOUYO[F:YLEII>8_D7+JMY:?DN%TJXJ[:I2K5TS&-=R&TL$ M+!&PM*L>VJ[Z0R"Z",_TGX.%X[CZO!&E6)C$*@8;"@ I+:KUP_1-5#;W&\[^ MRP.GV=A(VVI%;7A*Q'_ZB-]L.*V]?6>WL?P^C8^#^*F7=R!+]7*V\F MQ5X)4:W$(\&X M"WK%A =3[-L7A+$@1RY^XH:!AS4".(DXH,1<#IH%&\B !Z[D/L !%["ONEK% M^JTN)[R'0C0 _+]J-?9>"M][Q:;AK<3AYQ?80;G/!,@"Z=G>^,T!U/OLXV(8\U>DQSZ?T M\(CU/AP=7?8V<&%;QT&UQ!7\%O#$D\#5-P[ZQ7(WI@1.5_B^ MT<-^>M9X1G^K"7?MWX579=@W2"2?3Q3 8'_+!DDW?GSV_998]$/?^RKM^ &+ MI^#( >"GYZUGGTE\-<87:@A(L$+@_ ZXI-%6'X/:;^T!7_,1MVTFPY[TX_, MBEN-ULYRCFSAJA_\'#<=_B>.AR!+NL(5X[ZM+[Z!C>TW*IF\;;YY@?_,")O- M8B@/6DMWSVU8YHH[2HFX;"FR'A&9,FI4(F")@(^_C9L8MC2&R>[>CRN>W85GD<7(%<":-IJ2&NA?:UBEF^ MZ]Y+O311GC0"MIV])=3M/TU1L-D3"\\C,>'2I%6:#HB*[)806R,^@=YP]X?U M2RW8-H -%%G"*G+&]@Z6GRA93BLL47W=4/W :>Z7%)O8R-XDB ML*2,ZZZ,^CQAC;;=>HW$MEL">AZQZ(++F %P8A=I[VS_$$K93UVB?#KB?"[.\[.[O+' MKCQR'?;&F)!KQP'6EM0W@'>6J;PE J[-X98(N#[FTKWKJU:Y.2?9".,L@3S? M.OB_*9,\+E/]UH,X2@(N$;!$P,??QLTS*AXBG\'/I$E)KH_A.5AMJ<9+I[6$ M[FQKS_!*W%L_W-O9=P[:K4W#O;6P,]8R9:&7-S%,+O@R[(PRA/M]A7#WG>8* M(C-END*)Z^N'Z[O.;NMII.8\!>OI83,7POSEGD-)<)_5PC_ M-/,:EM5?'K[:V-CVL/F&VXT;[;9W\'QLCY &]HE=BNH!;T.=XELZEC1D\.S; M^YXTZJU=&:P6!6>;1R[1$?-GHF(YF"Y5O[/R@^_X,HG!,[S ]H1=V M^F?]!#DF3@I@,G#]Q(/O^SX+!W2K# #0,8]E&)"N. C#F(8*% ,E0JTRPDV8 MTH"")(AQ/,$D@E?*B0_G,12!B.#%]+F8(+@R(!!^"PCX'H*L:-]PP($O8I$M MJ!@TV>KKL^*4^.#2>."BP0\KP,^5M%L$6^;Y@/\6Q)LR!*W'\0^+$!%EC@4;5R")]R-U[V4I8) M[R]"*<#V:N5C&$5RJ6-BENOL".3G:N5\Q$%VN2(A"EU3:-/!.._\1,!CD[?2 M8$0]$CY)7O7/&!740?J]>9&L+8IL[>^UMJN5@\9.;;^YWUI7,)<_YVFI MC8U NP&.\'OX]]_ANL)X?'A1K?P!F'HMW4]B/:&\25P3W-GZ%6[L/Z\M\&M/ M4SL[;:"I5K-=:^PV=M<5S%7-3ENRQ/TH/,DW0MS^"NP?C,]NZ W7E,">O3WA MOX=2?!#:]3:S5S_S=7JQJN:\K>8LZ1FSDH7<0]#MPEH>C8A5>T5.^$J7IO1 M@K<:=P^R=QE09KC@BW=GW?^0H^7#Y<<3^.7_ %!+ P04 " &AZU8*8-N M2Q(1 !.7P $@ '1N<'A?.&LM,#4Q,S(T+FAT;>T\^U?BNM:_^U?DXZZY M1]>15WFC_Y9IVCMDEV M]CM[[R0]_<]TI*)G8E)%U\[^2L82?R&B2;JL:(.SO\J=BBC^]9_2P>G0@F[0 M5:-GD:%E&<5X?#*9Q":IF&X.XLE"H1"?LCX1NU-Q&MA/2"22\>^W-QUI2$8X MJFC4PII$YH-417L*A\]:YUU[IJKXNK(W[B2I^ IH:)47 [R=LW&[T=?5"NR: ML;M:;E>%ZFDAF5N'A]UC/F :UC?)< 8*R??S]LVBNQ7IG..RV2)W>Z< MT CA+3;T23]4+#9.+2Z'<8NONZ2/ M-^M>2_VP%L3F60JPFR*8+ET@-B_4TNQ5%(Z MC=N_#TY'Q,*(#8R27V/E^2Q2T36+:%:T.S. Q9+]=!:QR-2*<\.+PZBX#?+T M_Z)15%>(*A=1AU@GJ(%'I(BF\O0$B57^QT-"J#[<=;X(U8MRN06_&&(H&MUP M<*KRP,BQ?[@T;3X\G9X/VF)TIO! 0(D :?BO/"*:#/];=14/'OI8I>05D,X] MD&H:,']6 5 F5D5-)M-K,GM(@,M*IQ*I1'9SL-ES8&WU(?G@6+\-'UZ] H3P MT!EBD] 'X8'[.AL&Y>]> 88)N=IR0*56$ J#W=/E&?R2E6=$K9E*SB*R0@T5 MSXI(TS7"M%>9%IFV$1-4F#\HLDPTIL_L"7HUQB-B*I*MJU.KS->FAD:X*F("6LGH;R=^<,BY0L=H(/XZE4<?-\N#Y9/&@V9RY#&"D+J^@ *NV:56Q14H+[%TXB[;E4: J M(6/9\L)%CY@>1*PNK:5]&+P"F9\8JT?21HKTP MYXO\6)XT *S;["5_F8V.Z2TLS39YQ^>=QF%LZ>#@U' ]9!_TIXB2"<-"764$ MGK1!)JBMC[!V;+\X!C]M*OT3-,+F0-&**'&"F,9%L:H,X%$"0R%F!*( @P'V M^/?V6"71%A[PI MTTT@QAY^KF+I"0$,1'55D4\0HR=*E=^PJ"09%*>S"]GNGW3[1TK__E+\]) 0]]&P3[XM Q;>#K@W)ZX7-DM^%[/<-<1NK8HZW7*WUGF?*3NUREU; M[(JU#BHWJJCVO7)9;ES44*5Y>RMV.F*S\2(>.V'P/:9#R#DM'<968Y48$A*9 M=&'-K&_7%Y>P0/#[A;X3T=6;[5MT2@VL<2?/ KY"(L$CVFBTJDMC%CZQ?.%! MFD?;B[C[]_FW?%EJ%7Y_?8)X;MLXJN"-H[QS1DKYZ/5RW'0:9]B6/DZJ.U%5 M,)AVK=%%[5JKV>Y^E";2D.L@1\O2Q9K3A92Z8]CP@Z6C5Z)A8B,%),8NFFA0]EY)A@" D(M M1)ZAL]-,Y*/BP;+959;,KL4#S)H=?0;;WTVUVQU-+\]_W&=?97]VC>8LHDRM M(D-T!'V',I[- %NB^>TSF0BR3Q]RD=(MGH'(CQ&;Y(^SV#]=>]:!%]*[4,YE M54LYJF9GK6TR4"BKW5DL_P_6-*6BSK)9@?2:6SOZ9'(U8?9/'2EUFPWQ.VI= MEMNWY4KMKBM6RC<==-F\J8J-"P@HVJW8&O7:OY4?UJ9 #2?#-G87?80IH@:1 M6/8J(P68;5$$3@YLW3QZ/]6W<$\ET*2JP!2)%> C8+[LV<"R[#X[*'AB^GEH M+NFJB@T* ;O[%T_W3BW3'?5,3$N1L.KB 9&_DQ&>6O(2Z%3ZBS\)X/E%(&^Y MAGIX$^WCD:+.BB]QQPL=F+F!NHN:I)O@A7F1NF.!_ZK8Q=F*+H=H_W<-D+7R MR;3\NCC'XV=9_9R5'RQBF/HS4Z 51RNLVL=:7".E!GG&,E[K<)T_+3E41JD_ M0D8%GXSJBDJ G!XQ@P6">S_%N\SLZJG>W]X?I5;YO9B7U:>2T50VD2S\3_ W MZ>-O%T]%I]@F<=U:Q^S)D)RW4B2M/>6V9W9 M30$B4A)R$:3Z50ZETELR'KX M8;[&33E_[&>)X&;*HM\F1+TFNH*@E\H*#XN7\N#](0%KD\]U'/EG]NGK7IE1 MT4C]"1;;'50;&:H^(^:[D>PW(]308T?^>,AO)7$>)I0^ M8Z*U=F4OR[))*'5^W2@:209[M$NM/+G_]CC])>#M/5IFU:,%(,"\&;K%$!%V M+),0*\2C':]48\RM'*188F68 MP&G%P"HB4R*-+>69Y5O@X @]0H> ,&(8OV-BM1>*%]GOO_^5%Y*Y$PH]56(, M=8T@C:]@QY!+2NJ8I6X(FP0?2$!WD=&]HF-91\>8D9:A:[A6W782S:QX]5/K M/VZO5;ZRK7?.2.DPGQ6.-C4-UX7?Z!"MM1CIZV+1I_;]=#*8]06R?> O^"I: MR_-&2H5$.II/YH7WMH$]*=SCF$)L,&,>FTA/O!2+#7"#8&,L4.WI4]0CJCY! MBEVGK8/;1/GH->HK*JC=@4)!!RVBR41F%5ZJC,:JA36BCZDZ0Q1"#MJ?\9'V M *3W8&([$G%*OYXZR1C@F AK,[>MKZLP.1O'7+/"0D6*#BDAZ()HQ 07(&HP M=LP#Z(-R3(C9Z!X5]\>I?4MBRTQO-?Y).\9S;RH6B(A%VV/-"0-IL 5]H]W> MM3J]KCS+6]>,>[JN$JSQ$S5+MN4K\@6BQ=A;R*73X6L,_W5@"\$! :AY82## ML^? MH516L@XNN7?:^!;#(?)'*K4VTA()6+0\>C3R-=UCAU=522@1QO<@LV" MX:HAA:K!W:A>Z8KU5\9_&PK75Z%:Q>EUDEV,!W[: %;%FDSC:%+P2-:W=327 M:SH1LWM^'M$*CFA;)F'VP?L]GC8A] M1;%PW%XG:H 3E3R 7K3F9%J."H>]H\T$;_?]/*)/!XM>I'1,S!<50!.MIGAC MT7Y.VH<"I-_19PX(3U,/2T\#4@5BV#Z.;1309 M*FQ[U;.V.E/ >.U(VM"+J^<^< MS4^VO;Q5]58_$%RG[[+3^AQ9?EA &B))Q92^M+G@/7872E)JP453&0RM@*Y+ M)_)6VC^"(R9F>L$I[LQ&/5T]I$?_8'ZPG7&?@A#7!8*]@\G!FX53>.O.R!(_ MMV63TZZ2?M#H=V=B2#7.<:NSI-#C9AB\WJ:GV<=!WFSDRMM7''RUXN5I(3.' M=5!G%6)=>EJ_DJY3_D^CTR$'GQS#MVT^6!;CT?6/%*UGN\+VLO"5MWUS1DKL M,M+_O@"Z$!N$Q:2NX_27'$_AJS/SY0@GV(LK(7, 0/053(7,%#:#I/^\>4\%Z C[/C MP.Z4*SRWM6_<,?GRN=09FWRBP-3,VVA )K28Y%FA, [\#M8D!:L'6.*7KUEG M=J%?QJ9,[;T&V9-$>PZOVWQ-I@[Q/)/V.I48VMHVYIK$5>:?YW&VO):6"KB5 M9@=*K[B6%A)OA5Y+FU]C^\!K:9N(,B^D"HXL?9QE")T _%]C5FX#-#AV/'!= MY5/(C;PYUSD?LP%BR/* WO!+#>A@K[W'C_A-QY7)38*?HCT"%@T(&ASAW4_H M%=5"2F\.U#:YT?>:ZS5SZ_B8,]QK="SD8&MAM6"VX\J':)$1$F()8<.CMH7D MWE%J$SI6+7Y&I6D0TREZR@^T5'33B*%#ML R/R8D3BIN M" I/R9,C8*P&TT@L@V!,MSD.(TU'#"P68,-_C?E-"V3'#)#O24.42MI8Q% 9 M#,&8'S@P^"$C$P(/3 ED--A"LD*E,:7 $N@ $0C$CP"-LORFKZ@ $;.\8JCT M% L5"K%$$BSFF$M=F9^RA5X0[\R_LP MQW:&85_YBKW3ML0?=@/DG9P$D\F? MXR06KH ?'61;7;:/<'2(QOX,S_ &70F&OX$2K8@E<"UR)A,^8$_F4#Y:IT7+ MZ-IQR2(2W1AC5Q+AY<30>N%+.*2^1/9YVMS1XGAO%HYX ]2]$>%!(C^^-+9%HH1!/)V- :14H%>^W! M>[6%9"+]:B/X4YD;*;5X!-:V(S W+'-"OV/DOTN^"YZR#38@AJ?$2&0I?K-//$?S7\#LP\ MUV;^PO]G_K[,_QT2_YVL?AWQHE'NWK5KG_&:PUH-]GXQQ*X)_QHKIGTF3.\? M;+"C,SJOY[4B\W2(X@"7M"@VW?S>V2(U3Y+V1@@?K[,Z< V MNLA8L_0##@^/K:%N@AN5]Y;"!3-IWVE=0!:T/L^S#=%SBS9H[0#H+-(XBZ1V M?2QHDT]#O/KPRZMI\K1O 7Y)0AE>MMX9E]BW6(I+Z^>+^7!ZIRBA43=BJ-<)H_'S&5 MH4+ZGC)KD]\'#"9J)R'9D@M>$V&E3E"3YUJTB&XPM?Z0@"LX_GEK^+,:<(9^ M.SA__L W2Q_'=[%OS8GTY\=(:7\SHJYFV]F[5J] MJJ7*/W(=L]I0:UJ^F;E.-6ZP.,F7)\\M4KC*M\N9FZ^)1E>4,L+=.1%^XWMM M7*O1N(AK^1^7#?67=G>=OOJ6O_Y3LMU[KO MWE3OG\WQKW*N_/MG_:(C%5IB[UM%_-9KCL:7^?;W\\1]6[E__-KMM&>&2GO? MQ;'6CE/UQ[?Z8^UO0^K&\ZF_!]5\_,[(VQR).U]*YM_@+OT74$L#!!0 ( M :'K5B8MJ3A(0, ,L+ 1 =&YX<"TR,#(T,#4Q,RYX],_T'U:\<6AI(4 LFDY%*FD&8@MSYUA"V#)D)R)3DX^?I*OG$Q4*"MGZ3= M<\[N2KMRZRR>4O""A22888$4%R?@ ='(6/@5H5B #I^&%"NL'6FD M)J@[U2H"MKV#[@-F/A?W@VZA.U$JE$T(9[.9P_@+FG'Q+!V/3W<3'"JD(EFH M5>)*]NU&[Q/I%>2/1S*<'<<#\C2)V.>H,V)N?XBNSQ]'MXU9W7]#F'Y1TT;\ M]8XB^'H9#?B/;\>=-]CM]Q\O@_-N&K(EO0F>(J O@\FV9>K+RIO5'"[&L%JI MN/"IWQLF."L%-F-*V/,ZN-MH-&#BS:$E9#P2-)>N0>,>(8D+9>TE6_"$2868 MMX3W54%8!-=AZER"DK70HQ1*\Z8OT#MT/CJIQP827N,4%B R1' MB6CF6 )+HHUQ'(M-'4M$>YNGFX+K-DDWDK=K>F)HGB*F;KB8GJ! M Q11G<"O"%$2$.Q;0"$QQLHTEPR1AS>HY)V)&..Z@?44919C"T.B.[0P:).Y MT:;@%-_I5(%9Z E:EC9&V.%Z^BU _+:5+A=$1)WGMXV9V?,#+)UL M/C #'(!DT)JF)=J6).:ILS+;1."@;2D6AW9^CS]UV8YNF1QB(FP9M.2.5D\J M"YQ+(.&55$H/@1;A(1:*Z+Y=F/8T=:(,_78A##!QI 7@/ZRK4]?2Y7*A "N-[;;7,GWG>]Q+I+90S,[.>;8QV6[5KKE. M+/UYIOLD,3^!_9+(>0
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end XML 17 tnpx_8k-051324_htm.xml IDEA: XBRL DOCUMENT 0001430306 2024-05-13 2024-05-13 iso4217:USD shares iso4217:USD shares false 0001430306 8-K 2024-05-13 TONIX PHARMACEUTICALS HOLDING CORP. NV 001-36019 26-1434750 26 Main Street Chatham NJ 07928 (862) 904-8182 false false false false Common Stock TNXP NASDAQ false